Navigation Links
Bioniche Reports Fiscal 2009 Year-End Results
Date:9/18/2009 

       - revenues increase by 21% over Fiscal 2008, to $33.3 million -

    (all figures are in Canadian dollars unless otherwise noted)

BELLEVILLE, ON, Sept. 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

"We had a very successful year in terms of revenues generated by our base Animal Health business, experiencing 21% growth in a challenging global economy," said Graeme McRae, Chairman, President CEO of Bioniche Life Sciences Inc. "In addition, subsequent to the end of the fiscal year, we announced a transformative corporate event: The signing of a licensing agreement with Endo Pharmaceuticals Inc. for exclusive rights to develop and market UrocidinTM in the U.S. with an option for global rights."

Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing.

Subsequent to the year-end, the Company received an up-front payment of US$20 million from Endo and executed a series of transactions improving its capital structure. At present, the Company reports that its unaudited cash position, inclusive of restricted cash, at the end of August, 2009, was $16.6 million. This strong cash position is the net result of the closing of the License, Development and Supply Agreement as explained above, the repayment of the revolving credit facility and associated fees of $6.2M (US$5.3M), the sale of U.S. licensing rights to a product in the animal health market subsequent to June 30, 2009 for $0.9M (US$0.8M), fourth quarter working capital variations, and repayment of overdue outstanding payables. More information on the partnership transaction and other subsequent events is provided
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
2. Bioniche Repays Revolving Credit Facility
3. Bioniche Provides a Corporate Update
4. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
5. Bioniche Represented at House of Commons Sub-Committee on Food Safety
6. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
7. Bioniche Reports Fiscal 2009 Third Quarter
8. Bioniche Provides a Corporate Update
9. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
10. Bioniche Revolving Credit Facility Maturity Date Amended
11. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Forney, United States (PRWEB) May 25, 2013 ... oldest and largest underground shelter company in the ... and composite underground structures for over 35 years. ... of PROTECTION, U.S. Handbook of NBC Weapon Fundamentals ... is the United States’ bible on shelter engineering. ...
(Date:5/25/2013)... 25, 2013 Providing patients with their best ... team of weight management professionals. But, aside from educating patients ... Diet Doc’s hCG diets also provide patients, who ... childhood like bullying, more control over their lives by achieving ... with the underlying factors of weight gain derived from earlier ...
(Date:5/25/2013)... On May 20, 2013 the Sydney Morning ... discuss or plan for their eventual demise, but it is ... a Must-Do List to help people properly arrange for their ... personal fact sheet.” , While not a formal document, this ... data. It may include a summary of assets, debts, ...
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May ... brain cancer research and advocacy, comments on a new ... that shows incorporating cold atmospheric plasma into brain cancer ... , According to a Science Daily article, ... (MPE), biologists and physicians demonstrated the “synergistic effect of ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... be linked to abnormalities in a person,s body clock ... published today in the journal Nature Genetics . ... than normal blood sugar levels could partly be tackled ... College London, the French National Research Institute CNRS, Lille ...
... Nurses Association (ONA) and University Hospitals Geneva Medical,Center (University ... on Friday, December 5. To date, the parties have ... At issue are economic provisions including ... has indicated that they will,remove premium rate charts for ...
... a leader in pharmacy,automation, today demonstrated InSite(TM), its ... pharmacies provide unparalleled,support for extended care environments with ... developed in response to hospital pharmacies,increasing need to ... care and correctional care environments they support. , ...
... FRANCISCO, December 7, 2008) The largest study ever ... help prevent deadly blood clots in patients with cancer ... conference on Sunday, December 7, at 9:30 a.m., during ... Hematology in San Francisco, CA. Additional research being featured ...
... 6 The use of dexamethasone early in the treatment ... of childhood cancer, may help reduce the risk of relapse ... on Saturday, December 6, at 2:00 p.m., during the 50th ... Francisco, CA. Additional research will be featured at the press ...
... Cowboy is a new wine that will,help raise money for breast ... Vegas this month. , Purple ... of the,professional rodeo community,s commitment to end breast cancer, it,s a ... Vegas will host the ultimate championship of professional,rodeo -- the Wrangler ...
Cached Medicine News:Health News:Body clock linked to diabetes and high blood sugar in new study 2Health News:Body clock linked to diabetes and high blood sugar in new study 3Health News:University Hospitals Geneva Medical Center Registered Nurses to Strike on December 10 if Contract Agreement Cannot Be Reached 2Health News:Talyst Moves Patient Safety and Inventory Control Beyond the Hospital 2Health News:Talyst Moves Patient Safety and Inventory Control Beyond the Hospital 3Health News:Research highlights new approaches to prevent blood clots 2Health News:Research highlights new approaches to prevent blood clots 3Health News:Research highlights new approaches to prevent blood clots 4Health News:Research highlights new approaches to prevent blood clots 5Health News:Research highlights new approaches to prevent blood clots 6Health News:Research highlights new approaches to prevent blood clots 7Health News:Research highlights new approaches to prevent blood clots 8Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:The Days of Wine and Rodeo 2
(Date:5/24/2013)... , May 24, 2013 Solta Medical, Inc. ... medical aesthetics market, today reported Dr. Edward W. ... Company,s Board of Directors effective immediately.  Dr. Knowlton is the ... had served as a director since 1996. "On ... our management team, I would like to thank Ed for ...
(Date:5/24/2013)... BEIJING , May 24, 2013 China ... "Company"), a leading fully integrated plasma-based biopharmaceutical company in ... Company has recently learned from a public announcement issued ... a public company listed on Shenzhen Stock Exchange, that ... Chan ("Ms. Chan"), one of the shareholders ...
(Date:5/24/2013)... , May 24, 2013  Sinovac Biotech ... provider of biopharmaceutical products in China ... operating subsidiary company of Sinovac, obtained the Certificate ... Certificate) from the China State and Food Administration ... bulk production plants, and its Changping filing and ...
Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3
... 14 Researchers at the,Barbara Ann Karmanos ... support the role of inflammation in determining ... (Logo:, http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ), The abstract ... Non,Small Cell Lung Cancer in African American ...
... DIEGO and SUNNYVALE, Calif., April 14 ,Pharmacyclics, Inc. ... its,preclinical program evaluating PCI-32765, an orally available, selective,inhibitor ... receptor (BCR),modulated diseases such as lymphomas and autoimmune ... of the American Association for Cancer,Research (AACR) being ...
Cached Medicine Technology:Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women 2Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women 3Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases 2Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases 3
Cold light source single outlet....
Cold light source single outlet....
Cold light source single outlet....
Cold light source triple outlet....
Medicine Products: